Trust Signals
Written by: FormBlends Medical Team, reviewed 2026-05-29.
Evidence standard: Every major claim is graded in the Evidence Ledger below. Speculative claims are labeled as such. No dosing figures are presented as clinical recommendations.
Conflicts: FormBlends sells research peptides. This page discloses that relationship. The analysis below concedes where this stack has no human evidence and where alternatives outperform it.
Regulatory status: BPC-157 and TB 500 are research compounds. Neither is FDA-approved for any indication. WADA prohibits both.
Key Takeaways
- BPC-157 is a 15 amino-acid synthetic peptide (MW 1419.5 Da); TB 500 is a synthetic fragment of Thymosin Beta-4 covering residues 17-23 (the LKKTET actin-binding motif) with an approximate MW of 831.9 Da.
- No published human RCT exists for either peptide alone in musculoskeletal injury repair, and no combination trial exists. Stack evidence is rodent-level at best.
- The two peptides target different but potentially complementary pathways: BPC-157 centers on VEGFR2 and nitric oxide signaling, TB 500 on G-actin sequestration and integrin-linked kinase activation.
- WADA lists TB 500 explicitly under S2 (Peptide Hormones) and BPC-157 under S0; both are presumed detectable in sport anti-doping testing.
- Purity and endotoxin contamination from unregulated peptide suppliers represent a larger practical risk than the theoretical mechanism risk. A COA with HPLC purity above 98% and a clean LAL endotoxin assay is the minimum bar.
Direct Answer: What Is the BPC 157 with TB 500 Stack?
The BPC 157 with TB 500 stack, commonly called the "wolverine stack," combines two synthetic peptides with proposed complementary tissue-repair mechanisms. BPC-157 is thought to act locally on tendon and vascular remodeling via VEGFR2 and nitric oxide pathways. TB 500 is thought to act more systemically by sequestering G-actin and promoting cell migration. No human RCT exists for the combination.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What exactly are BPC 157 and TB 500?
- How do the mechanisms differ and why combine them?
- Evidence ledger: what does the research actually show?
- What doses and schedules are used in the stack?
- What most pages get wrong about the wolverine stack
- What about adding Sermorelin? The triple stack
- Honest head-to-head: stack vs. proven alternatives
- Operational guide: reading a COA and reconstitution math
- Stability and formulation gotchas
- Safety signals and who should not use this stack
- FAQ
What Exactly Are BPC 157 and TB 500?
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). It was isolated and characterized by Sikirnjak and colleagues from a protein fraction in human gastric juice. Molecular weight: 1419.5 Da. It is not naturally occurring at measurable systemic concentrations; it is entirely a research construct at doses studied.
TB 500 is a synthetic peptide corresponding to amino-acid residues 17-23 of Thymosin Beta-4 (TB4), a 43 amino-acid endogenous protein abundant in platelets and wound fluid. The active fragment sequence is Ac-LKKTET-OH (approximate MW 831.9 Da). Full-length Thymosin Beta-4 has been studied in small human trials for wound healing (RegeneRx Biopharmaceuticals trials, completed but not FDA-approved). TB 500 as a standalone fragment has not been studied in humans in published RCTs.
How Do the Mechanisms Differ and Why Combine Them?
The case for combining the two peptides rests on proposed mechanistic complementarity, not on a combination study. Here is what the available data actually shows for each pathway.
BPC-157 proposed mechanism: Multiple rodent studies (Sikiric and colleagues, University of Zagreb, published across Biomedicine and Pharmacotherapy and Current Pharmaceutical Design over roughly two decades) demonstrate upregulation of VEGFR2 (vascular endothelial growth factor receptor 2) expression in tendon fibroblasts. Separately, BPC-157 appears to modulate the nitric oxide system: in NO-deficient animal models, systemic BPC-157 reversed vasoconstriction and gut motility disruption, implicating an NO-pathway rescue effect. BPC-157 also promotes egr-1 (early growth response protein 1) transcription in tendon cells, which in turn drives collagen I and III gene expression in in vitro studies.
What that mechanism does NOT prove: In vitro VEGFR2 upregulation and rodent tendon force studies do not confirm that equivalent vascular remodeling or collagen synthesis occurs in humans at any dose. The translation gap is large.
TB 500 proposed mechanism: The LKKTET hexapeptide sequence in Thymosin Beta-4 is the actin-binding domain responsible for G-actin sequestration. By binding G-actin, TB4 and its fragment regulate actin polymerization dynamics and promote lamellipodia formation in migrating cells. Separately, full-length TB4 upregulates integrin-linked kinase (ILK), an adhesion kinase that promotes endothelial and cardiac progenitor cell survival. In rodent models of myocardial infarction and corneal wound healing, TB4 reduced infarct size and accelerated epithelial repair (Goldstein and colleagues; Smart and colleagues, published in Nature and Circulation respectively). TB 500 as the isolated fragment shares the actin-binding function; whether it replicates ILK effects of full-length TB4 is not clearly established.
Complementarity argument: BPC-157 is proposed to work most strongly at the structural/vascular level in localized connective tissue injury. TB 500 is proposed to promote cell migration and systemic progenitor mobilization. The two pathways are not redundant, which is the rational basis for combining them. The logic is plausible. The combination has not been tested.
Evidence Ledger: What Does the Research Actually Show?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| BPC-157 accelerates tendon-to-bone healing in rodents | Multiple rodent RCTs (Sikiric lab, Zagreb) | Positive | Moderate (animal) |
| BPC-157 upregulates VEGFR2 in fibroblast cultures | In vitro cell studies | Positive | Moderate (lab) |
| BPC-157 improves human musculoskeletal injury outcomes | No published human RCT | Unknown | Very Low |
| Full-length Thymosin Beta-4 (not TB 500) accelerated wound healing in small human trials | Phase II RCT (RegeneRx, stasis ulcers, n=75) | Positive (topical) | Low (small, single indication) |
| TB 500 (LKKTET fragment) accelerates healing in humans | No published human study | Unknown | Very Low |
| BPC-157 plus TB 500 combination is superior to either alone | No study (any species) | Unknown | Very Low |
| Thymosin Beta-4 (full length) promotes cardiac repair in rodent MI models | Multiple rodent studies (Smart et al., Circulation 2007) | Positive | Moderate (animal) |
| BPC-157 has no acute organ toxicity at study doses in rodents | Rodent toxicology studies | Neutral (no toxicity found) | Moderate (animal) |
| Sermorelin increases GH pulse amplitude and IGF-1 in adults | Human RCTs (Vittone et al. and others) | Positive | High (approved drug history) |
| Adding Sermorelin to BPC-157 and TB 500 improves outcomes vs. the pair alone | No study | Unknown | Very Low |
What Doses and Schedules Are Used in the Stack?
Important framing: The figures below reflect what appears in the research community and compounding pharmacy literature. They are NOT validated human clinical doses. Present them as reference points, not recommendations.
| Compound | Rodent study dose | Human protocol range discussed in literature | Route | Frequency cited |
|---|---|---|---|---|
| BPC-157 | 10 mcg/kg body weight (Sikiric studies) | 250 to 500 mcg per day | Subcutaneous, intramuscular, or oral (oral bioavailability debated) | Daily or twice daily |
| TB 500 | Variable across rodent studies; not easily extrapolated | 2 to 2.5 mg twice weekly (loading), then weekly | Subcutaneous or intramuscular | Twice weekly for 4-6 weeks, then weekly maintenance |
| Sermorelin (if included) | N/A (approved drug in humans) | 100 to 300 mcg | Subcutaneous, typically at bedtime | Daily or 5 days on, 2 off |
Cycle length discussed in the research community for the BPC-157 plus TB 500 stack is typically 4 to 8 weeks. No data establishes an optimal cycle length.
What Most Pages Get Wrong About the Wolverine Stack
This is the section commodity pages omit entirely.
1. TB 500 is not Thymosin Beta-4. Full-length TB4 is the molecule that has been in human trials (RegeneRx) and in the Goldstein and Smart rodent cardiac studies. TB 500 is the LKKTET fragment only. It shares actin-binding activity but it is not established to replicate all of TB4's ILK-mediated effects. Pages that present TB 500 and TB4 as interchangeable are wrong about the molecule.
2. Oral BPC-157 bioavailability in humans is not established. Rodent gastric studies suggest the peptide survives gastric acid to some degree (which is unsurprising given it is derived from gastric protein). But dose-linear oral bioavailability in humans, at the concentrations that would be needed for systemic effect, has not been measured. Pages that say "oral is as effective as injectable" have no human PK data to support this claim.
3. The "complementary mechanism" argument for the stack is a hypothesis, not a finding. No additive or synergistic effect has been demonstrated even in an animal model. The logic is reasonable, but the combination claiming superiority over either peptide alone is pure inference.
4. Impurity and endotoxin risk from unverified suppliers is the dominant real-world risk. Bacterial endotoxins from gram-negative contamination during synthesis cause injection-site reactions, flu-like symptoms, and at high levels, sepsis-like responses. A 5 mg vial of peptide from a supplier with no published COA carries endotoxin risk that dwarfs the theoretical peptide mechanism risk. This is almost never discussed.
5. WADA prohibition is often buried or omitted. Both compounds are prohibited in-competition and out-of-competition for athletes subject to WADA code. TB 500 is named explicitly in the S2 category. The window of detectability for TB 500 by the current WADA-accredited immunoassay method is not publicly quantified but is considered several days at minimum.
What About Adding Sermorelin? The Triple Stack
Sermorelin is a 29 amino-acid analogue of growth hormone-releasing hormone (GHRH). It was FDA-approved for pediatric GH deficiency (Geref) and has been studied in adults for age-related GH decline. Unlike BPC-157 and TB 500, Sermorelin has a known human PK profile: subcutaneous half-life of roughly 10 to 20 minutes, peak GH stimulation occurring within 30 to 60 minutes, and well-documented IGF-1 elevation in human subjects across multiple trials.
The rationale for adding Sermorelin to the BPC-157 plus TB 500 stack is that elevated GH and IGF-1 may provide an anabolic backdrop that amplifies connective tissue repair. This is biologically plausible: IGF-1 promotes collagen synthesis and satellite cell activation. However, there is no study, at any evidence level, testing whether Sermorelin augments outcomes from either repair peptide. The triple stack introduces a third variable with its own side-effect profile (edema, carpal tunnel symptoms, glucose tolerance effects at higher GH levels) and its own WADA prohibition status (GH secretagogues are S2 prohibited).
The Sermorelin plus BPC-157 stack search term reflects genuine user interest, but the honest answer is that adding Sermorelin raises the evidence floor from Very Low to Very Low with more unknowns.
Honest Head-to-Head: Stack vs. Proven Alternatives
| Intervention | Human RCT evidence for MSK injury | Effect size (where known) | Safety profile | Regulatory status | Where stack wins | Where stack loses |
|---|---|---|---|---|---|---|
| BPC-157 plus TB 500 stack | None | Unknown | Unknown long-term; impurity risk real | Research compound; WADA prohibited | Theoretical multi-pathway repair; novelty | Every other column |
| Physical therapy (progressive loading) | Extensive (Cochrane-level meta-analyses for tendinopathy) | Moderate to large for tendinopathy | Excellent | Standard of care | N/A | Slower initial symptom relief |
| PRP (platelet-rich plasma) injection | Moderate; conflicting RCTs for rotator cuff and knee | Small to moderate; inconsistent | Good; autologous | Cleared device; not FDA-approved drug indication | Contains endogenous TB4 and growth factors | Expensive; inconsistent prep standards |
| NSAIDs (short course) | Strong for acute pain and inflammation | Moderate for pain; no structural repair evidence | GI and renal risk with prolonged use | FDA-approved | Well-characterized; cheap | No tissue repair; GI risk |
| Corticosteroid injection | Strong for short-term pain relief | Large short-term, inferior at 6-12 months vs. PT | Tendon weakening risk with repeat injections | FDA-approved | Fast pain relief | Potential structural harm long-term |
The stack does not outperform any comparator on evidence. The only honest argument for using it is the theoretical mechanism hypothesis combined with a tolerance for uncertainty, in a context where established options have been tried.
Operational Guide: Reading a COA and Reconstitution Math
What a credible COA must include:
- HPLC purity: 98% or greater. Values below 95% suggest significant impurity fractions of unknown identity.
- Mass spectrometry: confirms the molecular ion matches the expected MW. For BPC-157, the expected [M+H]+ is approximately 1420.5 Da. For TB 500 (LKKTET), approximately 832.9 Da. If MS data is not on the COA, the supplier cannot confirm the correct peptide is present.
- Endotoxin (LAL assay): should be below 5 EU/mg for research use. Higher values indicate bacterial contamination during synthesis or lyophilization.
- Batch/lot number: traceable to the synthesis run. Generic or missing lot numbers mean no accountability.
Reconstitution math (example):
To prepare a BPC-157 solution at 500 mcg/mL from a 5 mg (5000 mcg) lyophilized vial: add 10 mL of bacteriostatic water. Draw BAC water slowly down the inside wall of the vial. Do not inject directly onto the peptide cake. Do not shake (swirl gently). Label with date. Store at 2 to 8 degrees Celsius. Each 1 mL drawn in a 1 mL insulin syringe = 500 mcg. Each 0.1 mL = 50 mcg. Use the same logic for any target concentration, dividing vial amount (in mcg) by desired concentration (in mcg/mL) to find the mL of BAC water to add.
What a degraded peptide looks like: Cloudiness or visible particulate in a reconstituted vial that was previously clear suggests aggregation or contamination. A yellow or brown tint in a solution that should be colorless suggests oxidation. Discard both. A vial that has been freeze-thawed repeatedly will show accelerated degradation, which is invisible but real.
Stability and Formulation Gotchas
This is the section almost no competitor page covers.
Lyophilized (dry) stability: Lyophilized peptide powders are generally stable for 24 months or longer when stored at minus 20 degrees Celsius in an airtight vial under inert atmosphere. At room temperature, stability declines over weeks to months depending on humidity. The peptide bond most vulnerable in BPC-157 is at the aspartate-glycine (Asp-Gly) motif, which is a known deamidation and isomerization site in peptides generally. Whether this specific site degrades meaningfully at room temperature within typical shipping windows is not precisely established in published literature, but the concern is real enough to make cold-chain shipping standard practice.
Reconstituted stability: Once reconstituted in bacteriostatic water, peptide stability is reduced substantially relative to the dry form. The benzyl alcohol preservative in BAC water inhibits microbial growth but does not stop chemical hydrolysis or oxidation. A commonly cited research-grade convention is use within 28 days of reconstitution when stored at 2 to 8 degrees Celsius. Sterile water (without benzyl alcohol) shortens usable window further because microbial contamination risk rises.
The mixing-in-one-syringe problem: Combining BPC-157 and TB 500 in the same syringe is convenient but introduces risk. No published compatibility data exists for this combination in solution. The different optimal pH conditions for each peptide (neither is published precisely, but peptide stability in solution is generally pH-sensitive) mean that mixing two solutions prepared independently could shift pH and accelerate degradation for one or both. Without a stability-indicating HPLC study on the mixture, this is an unknown. Separate injections at proximate sites is the more conservative approach.
Light exposure: Peptides containing aromatic amino acids (phenylalanine, tyrosine, tryptophan) are most vulnerable to UV degradation. BPC-157's sequence does not contain these residues, giving it somewhat lower photodegradation risk than many peptides. Nonetheless, storage in amber vials and away from direct light is standard practice and costs nothing.
Safety Signals and Who Should Not Use This Stack
This section addresses research-use safety context only and is not medical advice.
Known signals from existing studies: Rodent studies for BPC-157 have not identified acute hepatotoxicity, nephrotoxicity, or hematologic toxicity at doses studied. Thymosin Beta-4 in the RegeneRx Phase II wound healing trials (topical, not injectable) reported no serious adverse events attributable to the drug, with injection-site reactions being the most common finding in injectable TB4 research. These are small, short-duration datasets.
Pro-angiogenic concern: Both BPC-157 (via VEGFR2) and TB4 (via ILK-mediated endothelial survival) have proposed pro-angiogenic effects. VEGF pathway stimulation in a person with an occult or established malignancy is a theoretical concern, because tumor vascularization supports tumor growth. This is not a demonstrated effect at the doses and durations studied, but it is the principal theoretical oncologic risk and is essentially never discussed on commercial peptide pages.
Who should not use this stack: Anyone with a personal or family history of malignancy, anyone on anticoagulant therapy (angiogenic peptides may theoretically interact with vascular remodeling), athletes subject to WADA or USADA testing, pregnant or breastfeeding individuals, and anyone without access to medical oversight and a quality COA for the sourced product.
FAQ
What is the BPC 157 and TB 500 wolverine stack?
It is a research compound combination of BPC-157 (a 15 amino-acid pentadecapeptide derived from gastric juice protein) and TB 500 (a synthetic fragment of Thymosin Beta-4, specifically residues 17-23 of the full 43 amino-acid protein). Users combine them because the two peptides are proposed to work on overlapping but mechanistically distinct repair pathways.
Does combining BPC 157 and TB 500 have human clinical evidence?
No. As of 2026 there are no published human RCTs specifically evaluating the BPC 157 plus TB 500 combination. Evidence for the stack is extrapolated from separate rodent studies for each peptide. The confidence rating for stack-specific outcomes is Very Low.
What is the proposed mechanism difference between BPC 157 and TB 500?
BPC 157 is proposed to upregulate VEGFR2 signaling and modulate nitric oxide pathways to promote local angiogenesis and tendon-to-bone healing. TB 500 (Thymosin Beta-4 fragment) sequesters G-actin via the LKKTET motif, promotes actin polymerization, and upregulates integrin-linked kinase. They are not redundant: BPC 157 is considered more local and structural, TB 500 more systemic and cell-mobility focused.
What doses are used in the BPC 157 TB 500 stack?
Rodent studies typically use BPC 157 at 10 micrograms per kilogram. Human protocols discussed in the research community commonly reference BPC 157 at 250 to 500 mcg per day and TB 500 at 2 to 2.5 mg twice weekly, but these human doses have no RCT validation and are extrapolated from animal data and compounding pharmacy conventions.
How do you reconstitute BPC 157 and TB 500 for research use?
Each vial is typically reconstituted with bacteriostatic water (0.9% benzyl alcohol in sterile water). A common approach is adding 1 to 2 mL of BAC water to a 5 mg vial of either peptide, yielding 2500 to 5000 mcg/mL. Draw slowly down the vial wall, do not shake, and store reconstituted peptide at 2 to 8 degrees Celsius. Use within 28 days of reconstitution.
Can you mix BPC 157 and TB 500 in the same syringe?
Mixing is physically possible and sometimes done to reduce injection volume, but no published stability data confirms the two peptides are chemically compatible in solution. Without a COA or compatibility study, mixing in the same syringe introduces unknown degradation risk. Separate injections at separate sites is the more conservative approach.
What is the BPC 157, TB 500, and Sermorelin triple stack?
Some protocols add Sermorelin, a 29 amino-acid GHRH analogue, to produce a growth hormone secretagogue effect alongside the repair-focused peptides. The rationale is that elevated GH and IGF-1 may augment tissue remodeling. There is no combination human trial data for this triple stack, and adding a third compound increases the number of unknowns substantially.
Is the BPC 157 TB 500 stack detectable on drug tests?
WADA prohibits Thymosin Beta-4 and its fragments (including TB 500) under the S2 Peptide Hormones category. BPC 157 is currently prohibited under S0 (non-approved substances). Both are testable by urine and blood immunoassay. Athletes subject to anti-doping rules should assume both are detectable.
What are the known safety signals for BPC 157 and TB 500?
Rodent toxicology studies for BPC 157 have not identified acute organ toxicity at study doses, and Thymosin Beta-4 studies in small human trials (for wound healing and cardiac repair) reported mostly injection-site reactions and mild fatigue. No large-scale human safety data for either compound exists. Unknown long-term effects, impurity risk from unregulated sources, and potential pro-angiogenic effects in occult malignancy are the principal concerns.
How does the BPC 157 TB 500 stack compare to a standard physical therapy and NSAIDs protocol?
Physical therapy combined with NSAIDs has substantial human RCT evidence for soft tissue and tendon injuries. The BPC 157 TB 500 stack has zero human RCT evidence for any musculoskeletal indication. For evidence-based practice, the peptide stack is not a replacement for established rehabilitation. It is an experimental adjunct at best.
What should a COA for research-grade BPC 157 or TB 500 include?
A credible COA should include HPLC purity greater than 98%, mass spectrometry confirming the correct molecular weight (BPC 157: 1419.5 Da, TB 500 fragment: approximately 831.9 Da), endotoxin testing by LAL assay, and a batch number traceable to the synthesis run. Absence of any of these data points is a sourcing red flag.
Sources
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-1632.
- Sikiric P, Seiwerth S, Rucman R, et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2013;19(1):76-83.
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3
Related peptide guides